Santen Pharmaceutical Co., Ltd. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Profit Before Tax
47,442.00
48,166.00
37,449.00
-3,437.00
37,220.00
12,046.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-12,787.00
5,800.00
15,701.00
-6,460.00
1,854.00
-18,484.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
43,500.00
60,928.00
72,649.00
37,147.00
46,043.00
38,808.00
Cash Flow from Investing Activities
-12,974.00
-8,223.00
-6,145.00
-26,777.00
-35,169.00
-53,355.00
Cash Flow from Financing Activities
-49,348.00
-53,307.00
-34,031.00
-37,220.00
5,557.00
-16,685.00
Net Cash Inflow / Outflow
-12,122.00
-1,585.00
36,679.00
-25,111.00
20,125.00
-28,542.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
6,700.00
-983.00
4,206.00
1,739.00
3,694.00
2,690.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in JPY Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Santen Pharmaceutical Co., Ltd.
Figures in Million
consolidated Cash Flow Results
Change(JPY)
Change(%)
Profit Before Tax
47442
3744
43,698.00
1167.15%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-12787
7744
-20,531.00
-265.12%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
43500
25590
17,910.00
69.99%
Cash Flow from Investing Activities
-12974
-154
-12,820.00
-8324.68%
Cash Flow from Financing Activities
-49348
-7921
-41,427.00
-523.00%
Net Cash Inflow / Outflow
-12122
18719
-30,841.00
-164.76%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
6700
1204
5,496.00
456.48%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -28.60% vs -16.13% in Mar 2025
Mar'26
Mar'25
Change(%)
Cash Flow from Operating Activities
43,500.00
60,928.00
-28.60%






